We think Roche's drug portfolio and industry-leading diagnostics conspire to create maintainable competitive advantages. As the market leader in both biotech and diagnostics, this Swiss healthcare ...

The antibody-drug conjugate improved progression-free survival for patients previously treated with hormone therapy.

DelveInsight’s Advanced Cervical Cancer pipeline report depicts a robust space with 70+ active players working to develop 75+ ...